This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The State Institute of Public Health of the Czechoslovak Republic, which is being constructed in cooperation with the International Health Board of the Rockefeller Foundation, has put on the market the first of its serologic products. Up to the present, serums and bacterial vaccines have been imported from other countries. As state control was not exercised over them, the products were of bad quality. The institute has not been given a monopoly for either production or distribution, but it hopes to take hold of the market on the basis of superior quality. It is estimated that the consumption of biologic products in this country amounts to about $200,000 annually. Because of lack of suitable products, serums and bacterial vaccines in general have not found as much use in this country as elsewhere. Consequently, a recent issue of the Casopis Ceskych Lekaru (Journal of the Czech Physicians) contained a
PRAGUE. JAMA. 1926;87(17):1407–1408. doi:10.1001/jama.1926.02680170061026
Customize your JAMA Network experience by selecting one or more topics from the list below.